non-Hodgkin lymphoma Archives

The FDA has accepted TG Therapeutics’ filing for its lymphoma drug umbralisib, which if approved could compete against

FDA to decide on TG Therapeutics’ lymphoma drug early next year

https://pharmaphorum.com/news/fda-to-decide-on-tg-therapeutics-lymphoma-drug-early-next-year/

Incyte/Morphosys take on CAR-Ts with $198,000 per year antibody

Richard Staines cancer, DLBCL, Incyte, MorphoSys, non-Hodgkin lymphoma 0 Comment

Incyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope

Incyte/Morphosys take on CAR-Ts with $198,000 per year antibody

https://pharmaphorum.com/news/incyte-morphosys-take-on-car-ts-as-lymphoma-antibody-monjuvi-approved-in-us/

News/ News/ News/ Oncology/ R&D

Scopus Bio preps trials of gene-silencing immuno-oncology drug

Phil Taylor gene silencing, Haematology, immuno-oncology, non-Hodgkin lymphoma, Oncology, RNA interference, Scopus BioPharma 0 Comment

Scopus BioPharma has licensed a gene-silencing drug from California’s City of Hope hospital that is due to start

Scopus Bio preps trials of gene-silencing immuno-oncology drug

https://pharmaphorum.com/news/scopus-bio-preps-trials-of-gene-silencing-immuno-oncology-drug/

News/ News/ News/ Oncology/ R&D/ Top stories

AbbVie forges $3.9 billion oncology alliance with Genmab

Phil Taylor AbbVie, Genmab, Haematology, non-Hodgkin lymphoma, Oncology, partnership, R&D 0 Comment

AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed

AbbVie forges $3.9 billion oncology alliance with Genmab

https://pharmaphorum.com/news/abbvie-forges-3-9-billion-oncology-alliance-with-genmab/

Market Access/ News/ News/ News/ Oncology

NICE backs Celgene’s Revlimid for chemo-free lymphoma therapy

Phil Taylor Bristol-Myers Squibb, Celgene, follicular lymphoma, NICE, non-Hodgkin lymphoma, Revlimid 0 Comment

NICE has backed Celgene’s Revlimid for routine NHS use in another indication, follicular lymphoma, as part of a

NICE backs Celgene’s Revlimid for chemo-free lymphoma therapy

https://pharmaphorum.com/news/embargo-001-27-feb-nice-backs-celgenes-revlimid-for-chemo-free-lymphoma-therapy/

News/ News/ Oncology

Epizyme eyes lucrative use for newly-launched Tazverik

Richard Staines cancer, Constellation Pharmaceuticals, fda, follicular lymphoma, non-Hodgkin lymphoma, Pfizer, tazemetostat 0 Comment

US biotech Epizyme is gearing up for a potentially lucrative second indication for its Tazverik (tazemetostat), after the

Epizyme eyes lucrative use for newly-launched Tazverik

https://pharmaphorum.com/news/epizyme-eyes-lucrative-use-for-newly-launched-tazverik/

News/ News/ Oncology/ Top stories

FDA to fast-track review of BMS’ CAR-T, ahead of shareholder deadline

Richard Staines blood cancer, Bristol-Myers Squibb, cancer, CAR T, Celgene, non-Hodgkin lymphoma 0 Comment

Speculators who bought into a risky three-drug bet are still on track for a payout following Celgene’s merger

FDA to fast-track review of BMS’ CAR-T, ahead of shareholder deadline

https://pharmaphorum.com/news/fda-to-fast-track-review-of-bms-car-t-ahead-of-shareholder-deadline/

News/ News/ News/ Oncology/ R&D

MorphoSys gets $750m from Incyte for anti-CD19 cancer drug

Phil Taylor antibody, Incyte, MorphoSys, non-Hodgkin lymphoma, Oncology 0 Comment

Incyte has agreed a deal with Germany’s MorphoSys to license an antibody that could be an alternative to

MorphoSys gets $750m from Incyte for anti-CD19 cancer drug

https://pharmaphorum.com/news/morphosys-gets-750m-from-incyte-for-anti-cd19-cancer-drug/

Market Access/ News/ News/ News/ News/ Oncology/ Patients

Scotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphoma

Phil Taylor CAR T, Gilead Sciences, NHS, non-Hodgkin lymphoma, Oncology, Scotland, Yescarta 0 Comment

The Scottish Medicines Consortium has backed NHS funding for Gilead’s CAR-T therapy Yescarta for B-cell lymphomas, a few

Scotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphoma

https://pharmaphorum.com/news/scotland-says-yes-to-gileads-car-t-yescarta-for-lymphoma/

Trending

non-Hodgkin lymphoma

Login